CN105560252A - 一种宠物耳道疾病的复方液体滴剂 - Google Patents

一种宠物耳道疾病的复方液体滴剂 Download PDF

Info

Publication number
CN105560252A
CN105560252A CN201510954698.5A CN201510954698A CN105560252A CN 105560252 A CN105560252 A CN 105560252A CN 201510954698 A CN201510954698 A CN 201510954698A CN 105560252 A CN105560252 A CN 105560252A
Authority
CN
China
Prior art keywords
liquid drops
compound liquid
levofloxacin
permethrin
dexamethasone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201510954698.5A
Other languages
English (en)
Inventor
苏振霞
李相国
肖辉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Huaihai Institute of Techology
Original Assignee
Huaihai Institute of Techology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Huaihai Institute of Techology filed Critical Huaihai Institute of Techology
Priority to CN201510954698.5A priority Critical patent/CN105560252A/zh
Publication of CN105560252A publication Critical patent/CN105560252A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明公开了一种宠物耳道疾病的复方液体滴剂，它涉及药品技术领域；本发明的主要配方材料有左氧氟沙星、***、利多卡因、氯菊酯，其它辅料还包括有丙二醇、乙醇、丙三醇、纯净水；以上所述配方材料的质量配比为左氧氟沙星(5-15g)：***(0.5-2g)：利多卡因(5-15g)：95%的氯菊酯(0.5-3ml)：丙二醇(25-35ml)：乙醇(5-15ml)：丙三醇(15-25ml)：纯净水(80-120ml)；该配方的制作工艺流程为：①丙二醇加热，倒入***溶解，②乙醇加热倒入氯菊酯，使其溶解，停止加热，③加入100ml纯净水搅拌至左氧氟沙星、利多卡因溶解，④搅拌均匀即可。本发明有益效果为：它解决了犬猫因螨虫感染导致伴发中耳炎的症状，既能有效杀灭螨虫，又能有效治疗因螨虫感染伴发的炎症，而且它还具有用料简单、设计合理、制作成本低等优点。

Description

一种宠物耳道疾病的复方液体滴剂
技术领域
本发明涉及药品技术领域，具体涉及一种宠物耳道疾病的复方液体滴剂。
背景技术
目前国内只有人用耳道疾病的复方液体滴剂，其他剂型没有，宠物耳道疾病的复方液体滴剂更是没有。只有单一丙三醇物理去杀螨虫的产品，或氧氟沙星滴耳液。现有技术没法满足宠物用药：1、是宠物服用片剂不方便，2、宠物领域没有宠物耳道疾病的复方液体滴剂。
发明内容
本发明的目的是提供一种宠物耳道疾病的复方液体滴剂，它解决了犬猫耳科疾病无药可治的难题，有效的去杀了螨虫。
为了解决背景技术所存在的问题，本发明的主要配方材料有左氧氟沙星、***、利多卡因、氯菊酯，其它辅料还包括有丙二醇、乙醇、丙三醇、纯净水；以上所述配方材料的质量配比为左氧氟沙星(5-15g)：***(0.5-2g)：利多卡因(5-15g)：95％的氯菊酯(0.5-3ml)：丙二醇(25-35ml)：乙醇(5-15ml)：丙三醇(15-25ml)：纯净水(80-120ml)。
该配方的制作工艺流程为：①丙二醇加热，倒入***溶解，②乙醇加热倒入氯菊酯，使其溶解，③加入100ml纯净水搅拌至左氧氟沙星、利多卡因溶解，停止加热，④搅拌均匀即可。
采用上述结构后，本发明有益效果为：它解决了犬猫因螨虫感染导致伴发中耳炎的症状，既能有效杀灭螨虫，又能有效治疗因螨虫感染伴发的炎症，而且它还具有用料简单、设计合理、制作成本低等优点。
具体实施方式
为了使本发明的目的、技术方案及优点更加清楚明白，以下具体实施方式，对本发明进行进一步详细说明。应当理解，此处所描述的具体实施方式仅用以解释本发明，并不用于限定本发明。
本具体实施方式的主要配方材料有左氧氟沙星、***、利多卡因、氯菊酯，其它辅料还包括有丙二醇、乙醇、丙三醇、纯净水；以上所述配方材料的质量配比为左氧氟沙星(5-15g)：***(0.5-2g)：利多卡因(5-15g)：95％的氯菊酯(0.5-3ml)：丙二醇(25-35ml)：乙醇(5-15ml)：丙三醇(15-25ml)：纯净水(80-120ml)。
该配方的制作工艺流程为：①丙二醇加热，倒入***溶解，②乙醇加热倒入氯菊酯，使其溶解，加入100ml纯净水搅拌至左氧氟沙星、利多卡因溶解，停止加热，④搅拌均匀即可。
本配方添加了利多卡因有效缓解耳道疼痛，其中的丙三醇是物理疗法，有润滑耳道，物理驱螨虫的效果。
以上所述，仅用以说明本发明的技术方案而非限制，本领域普通技术人员对本发明的技术方案所做的其它修改或者等同替换，只要不脱离本发明技术方案的精神和范围，均应涵盖在本发明的权利要求范围当中。

Claims (2)

1.一种宠物耳道疾病的复方液体滴剂，其特征在于本发明的主要配方材料有左氧氟沙星、***、利多卡因、氯菊酯，其它辅料还包括有丙二醇、乙醇、丙三醇、纯净水；以上所述配方材料的质量配比为左氧氟沙星(5-15g)：***(0.5-2g)：利多卡因(5-15g)：95%的氯菊酯(0.5-3ml)：丙二醇(25-35ml)：乙醇(5-15ml)：丙三醇(15-25ml)：纯净水(80-120ml)。
2.根据权利要求1所述的一种宠物耳道疾病的复方液体滴剂，其特征在于该制剂配方的制作工艺流程为：①丙二醇加热，倒入***溶解，②乙醇加热倒入氯菊酯，使其溶解，③加入100ml纯净水搅拌至左氧氟沙星、利多卡因溶解，停止加热，④搅拌均匀即可。
CN201510954698.5A 2015-12-21 2015-12-21 一种宠物耳道疾病的复方液体滴剂 Pending CN105560252A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201510954698.5A CN105560252A (zh) 2015-12-21 2015-12-21 一种宠物耳道疾病的复方液体滴剂

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201510954698.5A CN105560252A (zh) 2015-12-21 2015-12-21 一种宠物耳道疾病的复方液体滴剂

Publications (1)

Publication Number Publication Date
CN105560252A true CN105560252A (zh) 2016-05-11

Family

ID=55871272

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201510954698.5A Pending CN105560252A (zh) 2015-12-21 2015-12-21 一种宠物耳道疾病的复方液体滴剂

Country Status (1)

Country Link
CN (1) CN105560252A (zh)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109464390A (zh) * 2018-12-29 2019-03-15 上海汉维生物医药科技有限公司 复方氯菊酯组合物及其制备方法
IT201900005280A1 (it) * 2019-04-05 2020-10-05 Ntc S R L Composizione otologica
WO2021056056A1 (en) * 2019-09-23 2021-04-01 Dermcare-Vet Pty Ltd Pharmaceutical compounds and methods of use

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103142701A (zh) * 2013-03-29 2013-06-12 武汉中博绿亚生物科技有限公司 一种用于宠物耳道混合感染的滴耳油剂及其制备方法
CN103830251A (zh) * 2012-11-23 2014-06-04 青岛康地恩动物药业有限公司 一种动物用氧氟沙星滴耳液的制备

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103830251A (zh) * 2012-11-23 2014-06-04 青岛康地恩动物药业有限公司 一种动物用氧氟沙星滴耳液的制备
CN103142701A (zh) * 2013-03-29 2013-06-12 武汉中博绿亚生物科技有限公司 一种用于宠物耳道混合感染的滴耳油剂及其制备方法

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109464390A (zh) * 2018-12-29 2019-03-15 上海汉维生物医药科技有限公司 复方氯菊酯组合物及其制备方法
IT201900005280A1 (it) * 2019-04-05 2020-10-05 Ntc S R L Composizione otologica
WO2020202056A1 (en) * 2019-04-05 2020-10-08 Ntc S.R.L. Otologic compositions
WO2021056056A1 (en) * 2019-09-23 2021-04-01 Dermcare-Vet Pty Ltd Pharmaceutical compounds and methods of use
CN115038452A (zh) * 2019-09-23 2022-09-09 德尔默克尔-维特私人有限公司 药物化合物和使用方法

Similar Documents

Publication Publication Date Title
JP2011509252A5 (zh)
CN105560252A (zh) 一种宠物耳道疾病的复方液体滴剂
CN104013573A (zh) 高含量液体聚维酮碘
EA202190115A1 (ru) Пленочные составы, содержащие дексмедетомидин, и способы их получения
MX2019008870A (es) Agente terapeutico para enfermedades hepaticas.
JP2017532369A5 (zh)
RU2016137926A (ru) Композиции грапипранта и способы их применения
CN105106215B (zh) 治疗奶牛急性***炎的软膏及其制备方法
CA2922913C (en) A veterinary method for inducing emesis
CN106821782A (zh) 宠物用滴耳剂及其制备方法
US20150342949A1 (en) Aripiprazole compositions and methods for its transdermal delivery
RU2008152691A (ru) Способ профилактики и лечения мастита у коров
CN102048822A (zh) 一种用于防治母猪子***的冲洗液
CN103340878B (zh) 一种兽用复方氧氟沙星溶液及其制备工艺
WO2014205519A1 (en) Antimicrobial compositions and methods of use
Kachhawa et al. Bovine ulcerative mammilitis and its therapeutic management
Bates Risks from detergent exposure
Syed et al. A successful treatment of bovine ulcerative mammilitis
US20150342989A1 (en) Compositions comprising non steroidal anti-inflammatory drugs and methods of use thereof
CN103830251A (zh) 一种动物用氧氟沙星滴耳液的制备
JP2006522061A5 (zh)
Kumar et al. A comparative evaluation of two therapies for the management of acute bovine mastitis
CN104523750A (zh) 用于治疗皮肤病的制剂及其配制方法
MX2023010847A (es) Formulaciones de tasipimidina y uso de las mismas.
CN105343122A (zh) 丙酸聚六亚甲基胍畜禽鱼药物制剂

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20160511